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Abstract (242 words) 48 
 49 
Objectives: Recently, following import by travel and migration, epidemic community-50 
associated methicillin-resistant Staphylococcus aureus (CA-MRSA) has caused nosocomial 51 
outbreaks in Europe, sometimes with a fatal outcome. We describe clinico-epidemiological 52 
characteristics of CA-MRSA detected by the European Network for the Surveillance of 53 
imported S. aureus (www. staphtrav.eu) from May 2011- November 2016.  54 
Methods: Sentinel surveillance at thirteen travel-clinics enrolling patients with travel-55 
associated skin and soft tissue infection (SSTI) and analysing lesion and nose swabs at one 56 
central laboratory. 57 
Results: 564 independent case-patients with SSTI were enrolled and had 374 (67%) S. aureus 58 
positive lesions, of which 14% (n=51/374) were MRSA. The majority of CA-MRSA isolates 59 
from SSTI was PVL-positive (n=43/51, 84%). The risk of methicillin-resistance in imported 60 
S. aureus varied by travel region (P<0.001) and was highest in Latin America (n=16/57, 28%, 61 
95%-CI 17.0-41.5) and lowest in Sub-Saharan Africa (n=4/121, 3%, 0.9-8.3). Major epidemic 62 
clones (USA300 / USA300 Latin-American Variant, Bengal Bay, South Pacific) accounted 63 
for more than one third (n=19/51, 37%) of CA-MRSA imports. CA-MRSA SSTI in returnees 64 
was complicated (n=31/51 multiple lesions, 61%; n=22/50 recurrences, 44%), led to health 65 
care contact (n=22/51 surgical drainage, 43%; n=7/50 hospitalisation, 14%), was 66 
transmissible (n=13/47 reported similar SSTI in non-travelling contacts, 28%), and associated 67 
with S. aureus nasal colonisation (n=28 of 51 CA-MRSA cases, 55%; 24 of 28 colonized with 68 
identical spa-type in nose and lesion, 85%). 69 
Conclusions: Travel-associated CA-MRSA SSTI is a transmissible condition that leads to 70 
medical consultations and colonisation of the infected host.  71 
 72 
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Introduction  77 
 Methicillin-resistant Staphylococcus aureus (MRSA) is known to cause recurrent skin 78 
and soft tissue infections (SSTI) in travellers [1-5] and nosocomial outbreaks [6] with 79 
potentially fatal outcomes [7] after introduction into the health care setting from abroad. 80 
Hence, systematic research on the clinical, microbiological, and epidemiological 81 
characteristics of imported MRSA and associated disease is of importance to travel medicine 82 
and public health practice alike. 83 
 84 
 The global distribution of community-associated methicillin-resistant S. aureus (CA-85 
MRSA) clones is heterogeneous and characterized by a regional predominance of particular 86 
clonal lineages [8]. Existing data on the global routes of CA-MRSA dissemination and the 87 
role of intercontinental travel in contributing towards the emergence of ‘pandemic’ clones is 88 
fragmented and restricted to reports on their sporadic import at a national or sub-national 89 
level. Systematic surveillance of CA-MRSA import on a larger scale, however, is hardly in 90 
place [9] since CA-MRSA and associated infections are not routinely notifiable in most 91 
European countries. To fill this gap, we analysed data collected from May 2011 to November 92 
2016 by StaphTrav (www.staphtrav.eu), a multi-centre network of thirteen European travel 93 
clinics aiming at the surveillance of S. aureus imported to Europe. Compared to a previous 94 
report published on SSTI cases caused by both, methicillin-sensitive and –resistant S. aureus 95 
and analysing data collected from May 2011 to December 2013 [1], the presented report 96 
incorporates an additional 246 case patients with imported SSTI and focuses solely on the 97 
clinical and (molecular-) epidemiological characteristics of MRSA and associated disease.  98 
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Methods 99 
Study population  100 
StaphTrav is a network of thirteen travel clinics in seven European countries that 101 
conducts surveillance on imported S. aureus (for details see www.staphtrav.eu). As 102 
predetermined in the network protocol, returning travellers and migrants seeking medical 103 
advice with acute or resolving SSTI with onset during intercontinental travel or within 30 104 
days after return (case definition) are approached for inclusion into a cross-sectional study. 105 
After informed consent by the patient or one legal guardian, nasal and lesion swabs are taken 106 
and sent to the central laboratory in Heidelberg for laboratory diagnostics. Clinical and patient 107 
information are collected during a face-to-face interview by the attending physician using a 108 
standardised questionnaire (publicly accessible on www.staphtrav.eu). 109 
 110 
Microbiological and molecular diagnostics  111 
 Detection of S. aureus was performed using Columbia Agar with 5% sheep blood and 112 
mannitol salt agar. Colonies typical for S. aureus were confirmed by coagulase test and nuc 113 
gene PCR, as previously described [1]. Susceptibility to commonly used antibiotics was 114 
tested by VITEK®2 (Biomerieux, France) and interpreted according to EUCAST clinical 115 
breakpoints. Phenotypic methicillin-resistance of S. aureus was confirmed by the presence of 116 
mecA.  117 
All MRSA were further characterized by SCCmec types (I-V) [10], PVL, spa and, for MRSA 118 
with the spa type t008, arginine catabolic mobile element (ACME) arcA [11]. Spa types were 119 
clustered into spa clonal complexes (spa-CC) using the Based Upon Repeat Pattern algorithm 120 
with parameters set to exclude if repeats were <5 and to cluster if cost ≤4 [12]. CA-MRSA 121 
MSLT ST8/spa t008/SCCmec IVa/IV consistent with the epidemic USA300 lineage were 122 
subject to whole genome sequencing. Genomic DNA was extracted using DNeasy Blood and 123 
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Tissue Kit (Qiagen, Germany) after prior lysis with lystostaphin (Genaxxon, Germany). 124 
Standard genomic library was prepared and sequenced with Illumina HiSeq (paired-end: 125 
2x150bp) by GATC Biotech AG (Konstanz, Germany). Raw sequences were trimmed for 126 
quality using sickle 1.33 (parameters : q > 30, l > 45) [15]. Cleaned sequences were 127 
assembled de novo using SPAdes 3.12.0 [16]. Contigs obtained from the assembly were 128 
therefore curated for length (> 1000 bp) and coverage (>10 X) to ensure no errors and 129 
contamination in the draft genome, giving an average coverage of 100x. Contigs were then 130 
annotated using Prokka 1.13 (based on genetic code table 11) [17] and the National Centre for 131 
Biotechnology Information (NCBI) Prokaryotic Genome Annotation Pipeline.  132 
Core genome (cgMLST) was obtained using Roary version 3.11.2 [18] with a definition of 133 
core as 100% of the strains sharing the gene. Phylogenetic tree was calculated from the 134 
alignment of the core genome using a generalized time-reversible model with fastTree 2.1.10 135 
[19]. Sequence data of the StaphTrav Project were deposited at NCBI 136 
(https://www.ncbi.nlm.nih.gov/) under the Bioproject no. PRJNA486096.  137 
 138 
Statistical Analysis 139 
 In case of clustered cases of SSTI (e.g. fellow travellers, household members), only 140 
the primary case was included into the analysis. Exact (binomial) 95% confidence intervals 141 
were calculated for proportions of MRSA among S. aureus positive SSTI by geographic 142 
region. A contingency table was constructed showing the proportion of MRSA among S. 143 
aureus by geographic region and their deviation from H0: “the proportion of MRSA is equal 144 
of categories of geographic region” tested using the χ2-test in Stata 13 (Stata Corp). 145 
 146 
Ethics 147 
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This study was approved by the Ethics Committee, Medical Faculty, Eberhard Karls 148 
Universität Tübingen, Germany and by the local institutional boards, if required.  149 
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Results 150 
 From May 2011 to November 2016, 564 independent cases of SSTI fulfilled the 151 
eligibility criteria and had been enrolled: 558 were travellers (345 leisure, 105 humanitarian 152 
and aid work, 63 visiting friends and relatives, 24 business, 19 education, 2 other reasons) and 153 
6 were migrants. S. aureus accounted for two-thirds (n=374/564, 67%) of all SSTI with onset 154 
during or up to 30 days post-travel. Of all patients with SSTI, 9% were caused by MRSA 155 
(n=51/564), and of all patients with S. aureus SSTI, 14% (n=51/374) were caused by MRSA. 156 
The majority of SSTI caused by S. aureus (n=237/374, 63%) presented as abscesses. 157 
 158 
Risk factors for travel-associated MRSA SSTI 159 
 The proportion of MRSA among S. aureus positive SSTI varied by geographic region 160 
(P<0.001, χ2-test, 5 degrees of freedom) and was highest in Latin America (n=16/57, 28%, 161 
95% CI 17.0-41.5), followed by South- and Southeast Asia (n=27/177, 15%, 10.3-21.4), but 162 
was comparably low in Sub-Saharan Africa (n=4/121, 3%, 0.9-8.3). Small sample size led to 163 
wide confidence intervals around the estimates for North Africa (n=1/4, 25%, 0.6-80.6), West 164 
Asia (n=2/3, 67%, 9.4-99.2) and Australia/Oceania (n=1/12, 8%, 0.2-38.5) (Figure 1).  165 
 166 
Molecular characteristics of MRSA from imported SSTI 167 
 Figure 2 summarizes the molecular population characteristics of CA-MRSA imported 168 
to Europe, 2011-2016. Over one third of all MRSA isolated from SSTI (n=19/51, 37%) 169 
belonged to one of the major pandemic clones circulating worldwide (Figure 2A, Table 1). 170 
Among these, strains of the USA300 MRSA clone dominated, accounting for almost one-fifth 171 
(n=9/51, 18%) of all imported MRSA in our study: four isolates belonged to the ST8/t008 172 
PVL+ SCCmec IVa arginine catabolic mobile element (ACME) positive clone and the other 173 
five belonged to the Latin-American variant of USA300, ST8/t008 PVL+ SCCmec IVc 174 
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ACME-negative clone, four of which carried the copper and mercury resistance (COMER) 175 
mobile genetic element. The one remaining ST8/t008 PVL+ SCCmec IVc ACME-negative 176 
COMER-negative isolate (STV073L) was imported from South Sudan (Table 1, Figure 3). 177 
The second most commonly isolated MRSA (n=6/51, 12%) were ST30/t019 with SCCmec 178 
type IVc and PVL+, consistent with the epidemic ‘Southwest Pacific’ CA-MRSA clone 179 
followed by ST772, t657/t345 SCCmec V, PVL+ CA-MRSA (n=4/51, 8%) also referred to as 180 
the Bengal Bay clone.  181 
 Classifying all imported CA-MRSA according to spa-CC yielded the following 182 
frequencies: 024/304 (n=14/51, 27%), spa-CC 148/791 (n=5/51, 10%), spa-CC 895 (n=5/51, 183 
10%) and two groups of related spa-types with no founder (t345/t657; n=4/51, 8%; t186/t239; 184 
n=2/51, 4%). One fourth (n=20/51, 39%) of imported CA-MRSA isolates were unrelated 185 
(singletons) and one isolate was not typeable (Figure 2B, Table 2).  186 
 187 
Dissemination of CA-MRSA through intercontinental travel 188 
 Almost all SSTI caused by USA300 and USA300-LV CA-MRSA were acquired in 189 
Latin America. South Pacific CA-MRSA SSTI were acquired in South-East Asia (the 190 
Philippines, n=3 and Singapore, n=1), Turkey (n=1) and Ghana (n=1). Four Bengal Bay CA-191 
MRSA were isolated from patients with travel to India (n=2), Egypt (n=1) and Indonesia 192 
(n=1) (Table 1). Table 2 summarizes information on other/non-epidemic CA-MRSA acquired 193 
abroad. 194 
 195 
Virulence, transmission, and co-resistance of imported MRSA and associated morbidity 196 
 The majority of CA-MRSA acquired abroad were PVL+ (n=43/51, 84%). About half 197 
of CA-MRSA SSTI patients suffered from recurrent infections (n=22/50, 44%) with more 198 
than half of those with recurrent S. aureus SSTI reporting two or more relapses (15/22, 68%). 199 
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S. aureus nasal colonisation was common among patients with MRSA SSTI (n=28/51, 55%), 200 
most of the times with the same strain in the nose and lesion (n=24/28, 86%) as determined 201 
by spa typing. About a quarter of CA-MRSA SSTI patients reported clinically similar SSTI in 202 
close contacts (n=13/47, 28%). 203 
 Substantial proportions of patients with SSTI caused by CA-MRSA suffered from 204 
multiple lesions (n=31/51, 61%) and required surgical drainage (n=22/51, 43%) or even in-205 
patient treatment (n=7/50, 14%).  206 
 207 
 Approximately half (n=31/51, 56%) of all imported MRSA isolates were co-resistant 208 
to at least one oral second-line agent (i.e. trimethoprim-sulfamethoxazole, ciprofloxacin, 209 
tetracycline, clindamycin and erythromycin), one third (n=18/51, 35%) to two or more, and 210 
one fifth to three or more (n=9/51, 18%) of these alternative oral antibiotics (Table 1 and 2). 211 
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Discussion 212 
 We show that overall about 14% of imported S. aureus SSTI treated at travel clinics is 213 
caused by MRSA. Major epidemic clones, such as USA300, Bengal Bay and South Pacific 214 
CA-MRSA accounted for about 37% of travel-associated MRSA SSTI. Infections caused by 215 
these pathogens were typically acquired at endemic destinations, i.e. Latin America [31], 216 
India [32], and the Philippines [33]. Taken together, these observations confirm that travel-217 
associated SSTI drives the spread of epidemic CA-MRSA over long distances [5, 9, 34]. 218 
  219 
 We found that most of the imported MRSA belonging to the USA300 lineage could be 220 
attributed to returnees from Latin America (7 of 9) and that many of these were infected with 221 
the USA300 Latin-American Variant (USA300-LV; 4 of 7). This genetically related clone has 222 
expanded in hospitals and communities across South America in recent years [19, 31, 35]. 223 
USA300-LV has become the most prevalent MRSA isolated from blood cultures in Colombia 224 
and Ecuador [18] and was found to colonize pigs in Cuba [35] – countries where four of the 225 
five cases with USA300-LV detected by our network were acquired. To date, its prevalence 226 
among CA-MRSA isolates in the European population is considered rare [36, 37]; however, 227 
reports of sporadic import, transmission, and micro-outbreaks suggest its expansive potential 228 
[13, 38]. Against this background, our findings identify travellers returning from Latin-229 
America to Europe with SSTI as important targets for the containment of epidemic USA300-230 
LV CA-MRSA.   231 
 232 
 The presented data indicates that recurrent SSTI (24/51, 47%), infections in non-233 
travelling household contacts (13/47, 28%), and nasal colonisation (28/51, 55%) – in 86% 234 
(24/28) with the infecting strain – are common in patients with travel-associated CA-MRSA. 235 
In conjunction with previous research that demonstrated identical spa-types in non-travelling 236 
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cases of SSTI secondary to imported cases of S. aureus infection [2], these findings support a 237 
substantial transmission potential of imported MRSA and suggest that nasal colonization 238 
represents an important reservoir from where the pathogen causes relapses and secondary 239 
cases. The high proportions of subjects requiring surgical drainage (22/51, 43%) and 240 
hospitalisation (7/50, 14%) document that health care contact is common in travellers 241 
returning with MRSA SSTI. Hence, to prevent nosocomial transmission, enhanced infection 242 
prevention and control measures have to be in place. This requirement becomes even more 243 
obvious when contextualizing our findings with the following details from published reports 244 
on sporadic in-hospital transmission of CA-MRSA: i) the same epidemic clones as those 245 
identified as imports in this study have been involved in nosocomial outbreaks in Europe [7, 246 
38-41], ii) in some of these outbreaks the primary case had recent exposure abroad [7, 39] and 247 
iii) suffered from travel-associated SSTI [7, 38].  248 
For the implementation of preventive measures, the substantial proportion of nasal 249 
colonization found in the present study suggests twofold: i.) that colonisation screening and 250 
pre-emptive isolation may prove useful as part of these measures and ii.) that these measures 251 
have to apply also to patients where the lesion has already resolved, as nasal colonisation may 252 
outlast infection by weeks or even months. In this context it is noteworthy, that household 253 
contacts of patients with travel-associated SSTI have also been colonized by imported CA-254 
MRSA [7, 38, 39] – further expanding the target group for potential colonisation screening to 255 
those living with CA-MRSA SSTI patients. Finally, health care institutions should educate 256 
their own personnel about the increased risk of introducing CA-MRSA into hospitals after 257 
exposure abroad [7, 39] and offer colonisation screening to employees reporting travel-258 
associated SSTI.  259 
 260 
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 S. aureus SSTI presents most commonly as abscess, making surgical drainage the 261 
mainstay of therapy. Since adjunctive antibiotic treatment of abscesses is beneficial in treating 262 
skin abscesses [42, 43], antimicrobial resistance has to be considered when choosing empiric 263 
therapy [44]. In this context, the presented data may prove valuable, as it shows a substantial 264 
prevalence of methicillin-resistance among imported S. aureus from Latin America only 265 
(28%, Figure 1), while this proportion among S. aureus from South- and Southeast Asia is 266 
around the threshold of resistance that would be considered relevant by most clinical 267 
microbiologists (15%), and clearly below in Sub-Saharan Africa (3%).  268 
 269 
 We established this ongoing surveillance to detect newly emerging methicillin-270 
resistant S. aureus clones with epidemic potential. Against this background, we detected four 271 
independent introductions of CA-MRSA belonging to MLST ST72/spa-CC148/297/PVL+ 272 
from Costa Rica (n=3) and New Zealand (n=1) to Germany. This finding is confirmed by data 273 
from the German National Surveillance Laboratory that also reported ST72 in 1.6% of 274 
putatively imported CA-MRSA isolates [45]. ST72 is reported to have entered the nosocomial 275 
setting and cause blood stream infections in the East Asia/Pacific Region [26] and Latin 276 
America [18]. Furthermore, we detected import of CA-MRSA ST398/t034/SCCmecV/PVL+ 277 
from Vietnam – a clone which is closely related to its PVL-negative, live-stock associated 278 
counterpart [27]. Our network detected the introduction of other regionally dominant clones 279 
such as the “Queensland” clone from Australia [25] and ST59/t437, highly endemic in East 280 
Asia [46], as well as several rare and even previously unreported CA-MRSA (Table 2).   281 
 282 
 Our study has limitations. First, part of the presented data has been previously 283 
published [1] which could be mistaken as duplicate publication. However, by doing so, 284 
StaphTrav acknowledges “surveillance” as “ongoing collection, collation, and analysis of data 285 
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and the timely dissemination of information to those who need to know so that action can be 286 
taken [47].” Second, due to the nature of our network of travel-clinics, this report has a focus 287 
on the import of S. aureus from tropical and subtropical regions to Europe. Thus, additional 288 
surveillance activities will be necessary to capture the import of epidemic MRSA from travel 289 
to the temperate zone. Third, it is likely that our case population recruited at travel clinics has, 290 
on average, suffered from more severe and complicated SSTI when compared to cases 291 
seeking care at primary care. This may have led to an over-estimation of the proportion of 292 
severe disease among all cases of imported S. aureus SSTI. Fourth, small sample size for 293 
returnees from Australia, North Africa, and West Asia led to imprecise estimates of the risk of 294 
MRSA among all S. aureus for these regions thus not allowing meaningful inferences on the 295 
effectiveness of oral beta-lactams for the treatment of patients returning from there.  296 
 297 
 In conclusion, our data supports that long-distance travel is an important driver for the 298 
spread of epidemic CA-MRSA over long distances. The presented findings on SSTI as a 299 
recurrent and highly transmissible condition in conjunction with reports on nosocomial 300 
outbreaks of epidemic CA-MRSA through travel-associated SSTI support the implementation 301 
of infection control and prevention measures when travellers with skin infections have contact 302 
to the health care system. Our data also suggest that caution should be exerted when caring 303 
for their household contacts, since these are commonly affected by secondary SSTI.  304 
  305 
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Table 1. Major epidemic CA-MRSA clones and associated SSTI in intercontinental travellers from Europe, 2011-2016 466 
 467 
 
ID Age Sex  Travel characteristics  
 Strain characteristics 
 
 Clinical characteristics 
 
region country purpose 
 
PVL spa spa-CC MLST SCC COMER ACME co-resistance 
 
 cont. rec. mult. hosp. surg. nasal 
USA300 
 
108 2 F 
 
Latin America Suriname leisure 
 
+ t008 024/304 ST8 IVa neg. pos. Ci, SXT, Er 
 
 no none yes no yes yes 
 
232 47 M 
 
Latin America Cuba VFR 
 
+ t008 024/304 ST8 IVa neg. pos. Ci, Er 
 
 no multiple no no no yes 
 
262 18 M 
 
Latin America Bahamas VFR 
 
+ t008 024/304 ST8 IVa neg. pos. Er 
 
 no single yes yes  yes no 
 
915 31 M 
 
Southeast Asia Thailand leisure 
 
+ t008 024/304 ST8 IVa neg. pos. Er 
 
 yes none yes no no no 
USA300-LV 
 
73 49 M 
 
Africa S.-Sudan aid 
 
+ t008 024/304 ST8 IVc neg. neg. Te 
 
 no none no no no yes 
 
101 59 M 
 
Latin America Colombia leisure 
 
+ t008 024/304 ST8 IVc pos. neg. Ci 
 
 missing none yes no no yes 
 
209 6 F 
 
Latin America Colombia VFR 
 
+ t008 024/304 ST8 IVc pos. neg. Er 
 
 yes multiple yes no no yes 
 
563 49 M 
 
Latin America Cuba VFR 
 
+ t008 024/304 ST8 IVc pos. neg. none 
 
 no multiple yes no yes yes 
 
658 50 M 
 
Latin America Cuba leisure 
 
+ t008 024/304 ST8 IVc pos. neg. none 
 
 no none no no no no 
South Pacific Clone 
 
18 31 F 
 
Southeast Asia Philippines VFR 
 
+ t019 single ST30 IVc n.a. n.a. none 
 
 yes none yes no no yes 
 
282 22 M 
 
Southeast Asia Philippines aid 
 
+ t019 single ST30 IVc n.a. n.a. none 
 
 no single yes no yes no 
 
483 49 M 
 
Southeast Asia Philippines leisure 
 
+ t019 single ST30 IVc n.a. n.a. none 
 
 missing none no yes yes no 
 
545 44 M 
 
Middle East Turkey VFR 
 
+ t019 single ST30 IVc n.a. n.a. none 
 
 yes none yes no no yes 
 573 53 F  Africa Ghana business  + t019 single ST30 IVc n.a. n.a. none   no none no yes yes yes 
 597 34 M  Southeast Asia Singapore leisure  + t019 single ST30 IVc n.a. n.a. none   no none yes no no yes 
Bengal Bay Clone 
 190 39 F  South Asia India leisure  + t657 NF1 ST772 V n.a. - Ci, SXT, Ge, Er   no none no yes yes yes 
 430 21 F  South Asia India leisure  + t657 NF1 ST772 V n.a. - Ci, SXT, Ge, Er   no none yes no yes no 
  514 21 M   Africa Egypt leisure   + t657 NF1 ST772 V n.a. - Ci, SXT, Ge, Er    yes none yes no yes no 
 579 26 M  Southeast Asia Indonesia leisure  + t345 NF1 ST772 V n.a. - Ci, SXT, Ge, Er   no multiple no no yes yes 
 468 
PVL=Panton Valentine Leukocidin; spa=gene encoding for S. aureus protein A; MLST=multi locus sequence type; SCC=staphylococcal cassette 469 
chromosome mec type; COMER=copper and mercury resistance mobile element; ACME=arginine catabolic mobile element; co-470 
resistance=concomitant phenotypic resistance; cont.=household contacts also affected by skin and soft tissue infection; rec.=recurrent skin and soft 471 
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tissue infection; mult.=multiple lesions per episode; hosp.=hospitalisation after return to home country; surg.=surgical drainage; nasal=nasal 472 
carriage of S. aureus; neg.=negative; pos.=positive; VFR=visiting friends and relatives; aid=humanitarian and aid work; Ci=ciprofloxacin; Er= 473 
erythromycin; Te =tetracyclin; Ge=gentamicin; SXT=trimethoprim-sulfamethoxazole; single=singleton; LV=Latin Variant; n.a.=not assessed; 474 
NF=no founder 475 
  476 
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Table 2. Non-epidemic MRSA and associated SSTI in intercontinental travellers from Europe, 2011-2016 477 
ID  Age Sex 
Travel characteristics     Strain characteristics   Clinical characteristics 
 
MLST assignment [Ref.]b, 
 endemic at travel region [Ref.]c, 
comment region country purpose   PVL spa type %a spa-CC SCC co-resist.   cont. rec. mult. hosp. surg nasal 
 
544 56 M Latin America Brazil leisure 
 
+ t197 0.04 024/304 IVc none 
 
no none yes no no no 
 
ST94 [16], [16] 
284 25 F Latin America Colombia aid work 
 
+ t13392 <0.01 singleton IVd none 
 
no single no no yes yes 
 
- 
932 23 F Latin America Costa Rica aid work   + t10437 <0.01 148/791 IVa none   no single no no no yes 
 
CC8 [17], - 
170 36 M Latin America Costa Rica VFR   + t148 0.31 148/791 IVa none   no none yes no yes no 
 
ST72 [16], [18] 
619 46 M Latin America Costa Rica leisure   + t3169 0.01 148/791 IVa Er, Te   no multiple yes no no yes 
 
ST72 [30], [18] 
635 26 F Latin America Costa Rica aid work   + t791 0.02 148/791 IVa none   yes mis. yes no yes yes 
 
ST72 [16], [18] 
600 64 M Latin America  Cuba education 
 
+ t008 6.02 024/304 IVd none 
 
no multiple yes no yes yes 
 
ST8/247/250/254 [16], [19]  
180 27 M Latin America Panama leisure   + t2393 0.02 NF2 IVc none   yes multiple yes no no no 
 
ST88 [20], [18] 
222 28 F Latin America Jamaica leisure 
 
+ t024 0.67 024/304 IVc SXT 
 
yes none yes no no yes 
 
ST8 [16], [19] 
229 29 M Africa Madagascar leisure   + t186 0.21 NF2 IVa SXT   no none yes no no no 
 
ST88 [16], [20] 
168 24 F Africa South Africa aid work 
 
+ t3812 <0.01 singleton IVc none 
 
no multiple yes yes yes no 
 
- 
496 23 F Middle East Israel leisure   + t6267 <0.01 895 nt Er   yes multiple yes no no yes 
 
CC5 [21], [22] 
268 21 F South Asia India aid work 
 
+ t304 0.44 024/304 IVa Ci, SXT 
 
no single no no yes yes 
 
ST8 [16], [23] 
495 57 M South Asia India leisure 
 
- t005 0.67 singleton IVc Ci, Cc, Er 
 
no none no no no no 
 
ST22/23/60 [16], [24] 
506 57 M South Asia Sri Lanka leisure   + t002 6.8 895 IVc Cc, Er   no none no no no no 
 
CC5/231 [16], [29] 
614 44 M South Asia Sri Lanka leisure   - t895 0.01 895 IVa Er, Ri   mis none yes no no yes 
 
- 
439 24 M South Asia Sri Lanka leisure 
 
- NT n/a n/a IVc Te 
 
yes none yes no no no 
 
- 
431 71 M South Asia Sri Lanka leisure 
 
+ t045 0.7 singleton IVc Ci, Er,Te 
 
no none yes yes no no 
 
ST5/225 [16], [16] 
505 61 M South East Asia Cambodia leisure 
 
+ t380 0.01 singleton V SXT, Te 
 
no single no no no no 
 
-  
448 24 M South East Asia Malaysia leisure 
 
- t5388 0.01 singleton IVc SXT 
 
yes multiple no no no no 
 
- 
194 54 M South East Asia Philippines leisure   - t002 6.8 895 IVc Cc, Er, Te   no none no no no yes 
 
ST5/225 [16], [16] 
444 46 F South East Asia Philippines VFR 
 
+ t104 0.01 024/304 IVc SXT 
 
no none yes no yes no 
 
- 
601 31 F South East Asia Philippines leisure 
 
- t1379 0.01 singleton IVc Er, Ri 
 
yes multiple no no yes yes 
 
- 
147 46 F South East Asia Philippines leisure   - t9999 <0.01 singleton IVc SXT   yes none yes no no yes 
 
- 
193 22 F South East Asia Thailand leisure 
 
+ t002 6.8 895 IVc none 
 
mis none yes no no  yes 
 
CC5/231 [16], [29]  
529 56 M South East Asia Thailand leisure 
 
- t1510 0.04 singleton IVa none 
 
no none no no no no 
 
- 
919 32 M South East Asia Thailand leisure 
 
+ t1671 0.01 singleton IVa Er 
 
no single no no no yes 
 
- 
289 23 F South East Asia Thailand aid work 
 
+ t202 0.1 singleton IVa none 
 
no multiple yes yes yes no 
 
ST93 [16], [25], “Queensland” clone 
599 35 F South East Asia Thailand leisure 
 
+ t437 0.73 singleton IVd Cc, Er 
 
no none no no yes no 
 
ST59 [16], [28] 
652 19 F South East Asia Vietnam leisure 
 
+ t034 1.98 singleton V Ci, Er, Te 
 
no multiple yes no yes yes 
 
ST398 [16], [27], LA-MRSA 
257 19 M South East Asia Vietnam aid work 
 
+ t202 0.1 singleton IVa none 
 
no multiple yes no no yes 
 
ST93 [16], [25], “Queensland” clone 
595 20 F Australia/Oceania New Zealand leisure   + t3169 0.01 148/791 IVa Er, Te   no multiple no mis yes no 
 
ST72 [30], [26] [22] 
 478 
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PVL=Panton Valentine Leukocidin; spa type=molecular typing based on DNA sequencing of the repeat region of the gene encoding for protein A 479 
of S. aureus; spa-CC=spa clonal complex as determined by Based Upon Repeat Pattern algorithm [12]; SCC= staphylococcal cassette chromosome 480 
mec type;  co-resist.=concomitant phenotypic resistance; cont.=case patient reports that household contacts are also affected by skin and soft tissue 481 
infection; rec.=recurrent skin and soft tissue infection; mult.=multiple lesions per episode; hosp.=hospitalisation after return to home country; 482 
surg.=surgical drainage; nasal=nasal carriage of S. aureus; MLST=multi locus sequence type; ST=sequence type; single=singleton; mis=missing; 483 
Cc=clindamycin; Er= erythromycin; Te =tetracyclin; Ge=gentamicin; SXT=trimethoprim-sulfamethoxazole; Ci=ciprofloxacin; Ri=rifampin; aid 484 
work=humanitarian and aid work; VFR=visiting friends and relatives; NF=no founder; NT=not typable; LA-MRSA=livestock associated MRSA 485 
a; % frequency of given spa-type among all entries in Ridom spa-server (http://www.spaserver.ridom.de/) 486 
b: reference that reports assignment of spa type of this isolate to a particular multi-locus sequence type (ST) or multi-locus clonal complex (CC)  487 
c; reference that reports methicillin-resistant S. aureus of given molecular type at region of travel 488 
d; SCCmec subtype not covered by PCR assay  489 
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Figure 1. Resistance to methicillin in S. aureus imported to Europe, by region of travel destination, StaphTrav Network 2011-2016 490 
 491 
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Displayed and codeed in blue are - for destinations with at least 10 S. aureus submissions - prevalence estimates of methicillin-resistance [95% 492 
confidence interval] among S. aureus imported from a geographic region together with estimates of Panton Valentine-Leukocidin (PVL)-positive 493 
isolates among methicillin-resistant S. aureus. Not displayed are estimates for regions with less than 10 S. aureus submitted, i.e. West-Asia (n=2/3, 494 
67% [9.4-99.2], 100% PVL+) and North Africa (n=1/4, 25% [0.6-80.6], 100% PVL+). Chi-squared-test with 5 degrees of freedom for H0: “The 495 
proportion of methicillin-resistant S. aureus is equally distributed over regions of travel destination.” gives P<0.001. 496 
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Figure 2. Molecular characteristics of imported MRSA, Europe, StaphTrav Network 2011-2016. 498 
 499 
 500 
 501 
A. Major epidemic clones among imported CA-MRSA 502 
B. Frequency of spa clonal complexes (spa-CC) among imported MRSA503 
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Figure 3. Relatedness of MRSA multi-locus sequence type 8 imported to Europe, 2011-2016 504 
(n=10). 505 
 506 
 507 
 508 
 509 
Unrooted maximum likelihood tree based on allelic differences in the core genome (core genome 510 
multi-locus sequence typing). Imported isolates of community-associated MRSA MLST ST8/spa 511 
t008 belong to two major clades: USA300-North American Clade (USA300-NA), shaded in 512 
blue, and USA300-Latin-American Variant (USA300-LV), shaded in red. Reference sequences 513 
for North and South American ST8-USA300 MRSA are FRP3757 [14] and CA12 [13], 514 
respectively, and marked in red and bold. Presence of the copper and mercury resistance 515 
(COMER) mobile element typically found in USA300 of the Latin-American Variant [15] is 516 
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marked by blue triangles. Presence of the arginine catabolic mobile element (ACME), which is 517 
the hallmark of the North American USA300 [15], is marked by red circles. The STV073L 518 
isolate, lacking both, COMER and ACME, was acquired in South Sudan, while the remaining 519 
isolates in the USA300-LV clade were imported from Cuba (n=2) and Colombia (n=2).  520 
